<DOC>
	<DOC>NCT02418793</DOC>
	<brief_summary>The purpose of the current Phase 1/2a single dose, dose-escalating study is to evaluate the acute safety, pharmacokinetics (PK) and pharmacodynamics (PD) properties of MOD-5014 in adult subjects with moderate/severe congenital hemophilia A or B. This will be a single-dose, open label, dose-escalating study. Each dose cohort will be concluded by a safety review, following which escalation to the next dose cohort will be approved.</brief_summary>
	<brief_title>A Study of a Long-Acting r-Factor 7a (Factor VIIa) in Adult Men With Hemophilia A or B</brief_title>
	<detailed_description />
	<mesh_term>Hemophilia A</mesh_term>
	<mesh_term>Hemophilia B</mesh_term>
	<mesh_term>Factor VIII</mesh_term>
	<criteria>Diagnosis of moderate or severe congenital Hemophilia A or B with or without inhibitors Diagnosis of any coagulation disorder other than Hemophilia A or B Receipt of any immunomodulatory therapy within 3 months prior to screening, with the exception of Hepatitis C or HIV therapy Have had, within one month prior to study drug administration, a major surgical procedure (e.g. orthopedic, abdominal) or have an elective surgery planned within the study period Use of any anticoagulant for arterial/venous obstructions and/or atrial fibrillation within 7 days prior to first study drug administration Malignancy within past 5 years (excluding nonmelanoma skin cancer)</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Hemophilia</keyword>
	<keyword>Factor VII</keyword>
	<keyword>Factor VIIa</keyword>
	<keyword>Inhibitors</keyword>
	<keyword>Long Acting</keyword>
</DOC>